| VERTEX PHARMACEUTICALS INC | 229.80 / +2.70% |
| Date/Time | 09/23 / 17:32 |
| Chg. / Chg.(%) | 6.05 / +2.70% |
| Bid | - |
| Ask | - |
| Open | 226.40 |
| Previous Close | 223.75 |
| High | 229.80 |
| Low | 226.40 |
| Volume [EUR] | 18,423.50 |
| Volume [Units] | 81 |
| Price fixings | 6 |
| ISIN | US92532F1003 |
| Security | VRTX |
| Exchange | Vienna Global Market |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 268.1500 |  |
291,036 |
| IEX | 268.18 | |
19,268 |
| Cboe US | 268.15 | |
16,099 |
| TradeGate | 229.400 | |
184 |
| Vienna Globa.. | 229.80 |  |
81 |
| Frankfurt | 227.2000 | |
14 |
| Stuttgart | 227.300 | |
10 |
| Xetra | 229.65 | |
6 |
| München | 224.95 | |
0 |
| Düsseldorf | 226.30 | |
0 |
| Berlin | 224.95 | |
0 |
| Hannover | 225.05 | |
0 |
| Hamburg | 225.05 | |
0 |
| Lang & Schwa.. | 229.700 | |
|
| gettex | 229.650 | |
|
| London Inter.. | 262.40 | 58 | |
| Mexico | 5,642.00 | 140 | |
| SIX Swiss Ex.. | 170.61 |
News
- Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
13:00 - GlobeNewswire - ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution
09/22/2020 / 16:55 - GlobeNewswire - CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease
09/22/2020 / 15:00 - GlobeNewswire - Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19
09/21/2020 / 17:01 - GlobeNewswire - Colorescience® Announces Successful Completion of $30 Million Debt Financing
09/14/2020 / 13:00 - GlobeNewswire
Real-time